Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Article Swipe

View

Carlotta Antoniotti , Alessandra Boccaccino , Robert S. Seitz , Mirella Giordano , Aurélie Catteau , Daniele Rossini , Filippo Pietrantonio , Lisa Salvatore , Kimberly McGregor , Francesca Bergamo , Veronica Conca , Simone Leonetti , Federica Morano , Giorgio Papiani , Emiliano Tamburini , Maria Bensi , Sabina Murgioni , Douglas Teller Ross , Alessandro Passardi , Isabelle Boquet , Tyler J. Nielsen , Jérôme Galon , Matthew G. Varga , Brock L. Schweitzer , Chiara Cremolini ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.27030781.v1

Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.

Related Topics

Concepts

Atezolizumab Bevacizumab Gene signature Medicine Signature (topology) Colorectal cancer Oncology Internal medicine Cancer research Cancer Gene Immunotherapy Gene expression Chemotherapy Biology Genetics Nivolumab Mathematics Geometry

Metadata

Type: preprint
Language: en
Landing Page: http://doi.org/10.1158/1078-0432.27030781.v1
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4402819795

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4402819795

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.27030781.v1

Digital Object Identifier
Title: Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-09-16

Full publication date if available
Authors: Carlotta Antoniotti, Alessandra Boccaccino, Robert S. Seitz, Mirella Giordano, Aurélie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jérôme Galon, Matthew G. Varga, Brock L. Schweitzer, Chiara Cremolini

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.27030781.v1

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.27030781.v1

Direct OA link when available
Concepts: Atezolizumab, Bevacizumab, Gene signature, Medicine, Signature (topology), Colorectal cancer, Oncology, Internal medicine, Cancer research, Cancer, Gene, Immunotherapy, Gene expression, Chemotherapy, Biology, Genetics, Nivolumab, Mathematics, Geometry

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4402819795
doi	https://doi.org/10.1158/1078-0432.27030781.v1
ids.doi	https://doi.org/10.1158/1078-0432.27030781.v1
ids.openalex	https://openalex.org/W4402819795
fwci	0.0
type	preprint
title	Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11067
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.996399998664856
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	Colorectal Cancer Treatments and Studies
topics[1].id	https://openalex.org/T10158
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9871000051498413
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	Cancer Immunotherapy and Biomarkers
topics[2].id	https://openalex.org/T10696
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9456999897956848
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2740
topics[2].subfield.display_name	Pulmonary and Respiratory Medicine
topics[2].display_name	Gastric Cancer Management and Outcomes
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2775949291
concepts[0].level	5
concepts[0].score	0.9291442036628723
concepts[0].wikidata	https://www.wikidata.org/wiki/Q20707748
concepts[0].display_name	Atezolizumab
concepts[1].id	https://openalex.org/C2777802072
concepts[1].level	3
concepts[1].score	0.8626484274864197
concepts[1].wikidata	https://www.wikidata.org/wiki/Q413299
concepts[1].display_name	Bevacizumab
concepts[2].id	https://openalex.org/C2779733811
concepts[2].level	4
concepts[2].score	0.6440705060958862
concepts[2].wikidata	https://www.wikidata.org/wiki/Q5531562
concepts[2].display_name	Gene signature
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.6382129788398743
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C2779696439
concepts[4].level	2
concepts[4].score	0.6377162933349609
concepts[4].wikidata	https://www.wikidata.org/wiki/Q7512811
concepts[4].display_name	Signature (topology)
concepts[5].id	https://openalex.org/C526805850
concepts[5].level	3
concepts[5].score	0.6354318857192993
concepts[5].wikidata	https://www.wikidata.org/wiki/Q188874
concepts[5].display_name	Colorectal cancer
concepts[6].id	https://openalex.org/C143998085
concepts[6].level	1
concepts[6].score	0.6018134355545044
concepts[6].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[6].display_name	Oncology
concepts[7].id	https://openalex.org/C126322002
concepts[7].level	1
concepts[7].score	0.5229398012161255
concepts[7].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[7].display_name	Internal medicine
concepts[8].id	https://openalex.org/C502942594
concepts[8].level	1
concepts[8].score	0.39452624320983887
concepts[8].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[8].display_name	Cancer research
concepts[9].id	https://openalex.org/C121608353
concepts[9].level	2
concepts[9].score	0.368734210729599
concepts[9].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[9].display_name	Cancer
concepts[10].id	https://openalex.org/C104317684
concepts[10].level	2
concepts[10].score	0.33076202869415283
concepts[10].wikidata	https://www.wikidata.org/wiki/Q7187
concepts[10].display_name	Gene
concepts[11].id	https://openalex.org/C2777701055
concepts[11].level	3
concepts[11].score	0.23257678747177124
concepts[11].wikidata	https://www.wikidata.org/wiki/Q1427096
concepts[11].display_name	Immunotherapy
concepts[12].id	https://openalex.org/C150194340
concepts[12].level	3
concepts[12].score	0.2092573642730713
concepts[12].wikidata	https://www.wikidata.org/wiki/Q26972
concepts[12].display_name	Gene expression
concepts[13].id	https://openalex.org/C2776694085
concepts[13].level	2
concepts[13].score	0.16725322604179382
concepts[13].wikidata	https://www.wikidata.org/wiki/Q974135
concepts[13].display_name	Chemotherapy
concepts[14].id	https://openalex.org/C86803240
concepts[14].level	0
concepts[14].score	0.1507469117641449
concepts[14].wikidata	https://www.wikidata.org/wiki/Q420
concepts[14].display_name	Biology
concepts[15].id	https://openalex.org/C54355233
concepts[15].level	1
concepts[15].score	0.0741967260837555
concepts[15].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[15].display_name	Genetics
concepts[16].id	https://openalex.org/C2780030458
concepts[16].level	4
concepts[16].score	0.06967651844024658
concepts[16].wikidata	https://www.wikidata.org/wiki/Q7041828
concepts[16].display_name	Nivolumab
concepts[17].id	https://openalex.org/C33923547
concepts[17].level	0
concepts[17].score	0.06641122698783875
concepts[17].wikidata	https://www.wikidata.org/wiki/Q395
concepts[17].display_name	Mathematics
concepts[18].id	https://openalex.org/C2524010
concepts[18].level	1
concepts[18].score	0.0
concepts[18].wikidata	https://www.wikidata.org/wiki/Q8087
concepts[18].display_name	Geometry
keywords[0].id	https://openalex.org/keywords/atezolizumab
keywords[0].score	0.9291442036628723
keywords[0].display_name	Atezolizumab
keywords[1].id	https://openalex.org/keywords/bevacizumab
keywords[1].score	0.8626484274864197
keywords[1].display_name	Bevacizumab
keywords[2].id	https://openalex.org/keywords/gene-signature
keywords[2].score	0.6440705060958862
keywords[2].display_name	Gene signature
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.6382129788398743
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/signature
keywords[4].score	0.6377162933349609
keywords[4].display_name	Signature (topology)
keywords[5].id	https://openalex.org/keywords/colorectal-cancer
keywords[5].score	0.6354318857192993
keywords[5].display_name	Colorectal cancer
keywords[6].id	https://openalex.org/keywords/oncology
keywords[6].score	0.6018134355545044
keywords[6].display_name	Oncology
keywords[7].id	https://openalex.org/keywords/internal-medicine
keywords[7].score	0.5229398012161255
keywords[7].display_name	Internal medicine
keywords[8].id	https://openalex.org/keywords/cancer-research
keywords[8].score	0.39452624320983887
keywords[8].display_name	Cancer research
keywords[9].id	https://openalex.org/keywords/cancer
keywords[9].score	0.368734210729599
keywords[9].display_name	Cancer
keywords[10].id	https://openalex.org/keywords/gene
keywords[10].score	0.33076202869415283
keywords[10].display_name	Gene
keywords[11].id	https://openalex.org/keywords/immunotherapy
keywords[11].score	0.23257678747177124
keywords[11].display_name	Immunotherapy
keywords[12].id	https://openalex.org/keywords/gene-expression
keywords[12].score	0.2092573642730713
keywords[12].display_name	Gene expression
keywords[13].id	https://openalex.org/keywords/chemotherapy
keywords[13].score	0.16725322604179382
keywords[13].display_name	Chemotherapy
keywords[14].id	https://openalex.org/keywords/biology
keywords[14].score	0.1507469117641449
keywords[14].display_name	Biology
keywords[15].id	https://openalex.org/keywords/genetics
keywords[15].score	0.0741967260837555
keywords[15].display_name	Genetics
keywords[16].id	https://openalex.org/keywords/nivolumab
keywords[16].score	0.06967651844024658
keywords[16].display_name	Nivolumab
keywords[17].id	https://openalex.org/keywords/mathematics
keywords[17].score	0.06641122698783875
keywords[17].display_name	Mathematics
language	en
locations[0].id	doi:10.1158/1078-0432.27030781.v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	http://doi.org/10.1158/1078-0432.27030781.v1
locations[1].id	pmh:oai:figshare.com:article/27030781
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306400572
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	OPAL (Open@LaTrobe) (La Trobe University)
locations[1].source.host_organization	https://openalex.org/I196829312
locations[1].source.host_organization_name	La Trobe University
locations[1].source.host_organization_lineage	https://openalex.org/I196829312
locations[1].license	cc-by
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Image
locations[1].license_id	https://openalex.org/licenses/cc-by
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name
locations[1].landing_page_url	https://figshare.com/articles/figure/Supplementary_Figure_S2_from_An_immune-related_gene_expression_signature_predicts_benefit_from_adding_atezolizumab_to_FOLFOXIRI_plus_bevacizumab_in_metastatic_colorectal_cancer/27030781
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5080776095
authorships[0].author.orcid	https://orcid.org/0000-0001-6881-3188
authorships[0].author.display_name	Carlotta Antoniotti
authorships[0].author_position	first
authorships[0].raw_author_name	Carlotta Antoniotti
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5056137510
authorships[1].author.orcid	https://orcid.org/0000-0001-7242-4396
authorships[1].author.display_name	Alessandra Boccaccino
authorships[1].author_position	middle
authorships[1].raw_author_name	Alessandra Boccaccino
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5033135467
authorships[2].author.orcid	https://orcid.org/0000-0002-5806-2840
authorships[2].author.display_name	Robert S. Seitz
authorships[2].author_position	middle
authorships[2].raw_author_name	Robert Seitz
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5017086518
authorships[3].author.orcid	https://orcid.org/0009-0003-0445-4501
authorships[3].author.display_name	Mirella Giordano
authorships[3].author_position	middle
authorships[3].raw_author_name	Mirella Giordano
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5057209749
authorships[4].author.orcid	https://orcid.org/0000-0002-1151-7019
authorships[4].author.display_name	Aurélie Catteau
authorships[4].author_position	middle
authorships[4].raw_author_name	Aurélie Catteau
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5103163013
authorships[5].author.orcid	https://orcid.org/0000-0002-6114-7335
authorships[5].author.display_name	Daniele Rossini
authorships[5].author_position	middle
authorships[5].raw_author_name	Daniele Rossini
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5079437223
authorships[6].author.orcid	https://orcid.org/0000-0002-8530-8420
authorships[6].author.display_name	Filippo Pietrantonio
authorships[6].author_position	middle
authorships[6].raw_author_name	Filippo Pietrantonio
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5026748433
authorships[7].author.orcid	https://orcid.org/0000-0003-3864-0719
authorships[7].author.display_name	Lisa Salvatore
authorships[7].author_position	middle
authorships[7].raw_author_name	Lisa Salvatore
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5016264665
authorships[8].author.orcid	https://orcid.org/0000-0002-9185-5869
authorships[8].author.display_name	Kimberly McGregor
authorships[8].author_position	middle
authorships[8].raw_author_name	Kimberly McGregor
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5028325185
authorships[9].author.orcid	https://orcid.org/0000-0002-8795-4653
authorships[9].author.display_name	Francesca Bergamo
authorships[9].author_position	middle
authorships[9].raw_author_name	Francesca Bergamo
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5004626743
authorships[10].author.orcid	https://orcid.org/0000-0001-7713-4005
authorships[10].author.display_name	Veronica Conca
authorships[10].author_position	middle
authorships[10].raw_author_name	Veronica Conca
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5072473792
authorships[11].author.orcid	https://orcid.org/0000-0001-6860-8635
authorships[11].author.display_name	Simone Leonetti
authorships[11].author_position	middle
authorships[11].raw_author_name	Simone Leonetti
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5064495942
authorships[12].author.orcid	https://orcid.org/0000-0002-5306-3596
authorships[12].author.display_name	Federica Morano
authorships[12].author_position	middle
authorships[12].raw_author_name	Federica Morano
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5033032136
authorships[13].author.orcid	https://orcid.org/0009-0001-4177-8535
authorships[13].author.display_name	Giorgio Papiani
authorships[13].author_position	middle
authorships[13].raw_author_name	Giorgio Papiani
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5019332793
authorships[14].author.orcid	https://orcid.org/0000-0003-4619-7091
authorships[14].author.display_name	Emiliano Tamburini
authorships[14].author_position	middle
authorships[14].raw_author_name	Emiliano Tamburini
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5074681974
authorships[15].author.orcid	https://orcid.org/0000-0002-5647-0525
authorships[15].author.display_name	Maria Bensi
authorships[15].author_position	middle
authorships[15].raw_author_name	Maria Bensi
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5057503389
authorships[16].author.orcid	https://orcid.org/0000-0002-4682-9872
authorships[16].author.display_name	Sabina Murgioni
authorships[16].author_position	middle
authorships[16].raw_author_name	Sabina Murgioni
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5008822450
authorships[17].author.orcid
authorships[17].author.display_name	Douglas Teller Ross
authorships[17].author_position	middle
authorships[17].raw_author_name	Douglas Teller. Ross
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5087670194
authorships[18].author.orcid	https://orcid.org/0000-0002-7099-240X
authorships[18].author.display_name	Alessandro Passardi
authorships[18].author_position	middle
authorships[18].raw_author_name	Alessandro Passardi
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5043534813
authorships[19].author.orcid	https://orcid.org/0000-0002-2028-5846
authorships[19].author.display_name	Isabelle Boquet
authorships[19].author_position	middle
authorships[19].raw_author_name	Isabelle Boquet
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5050750573
authorships[20].author.orcid	https://orcid.org/0000-0002-9576-2838
authorships[20].author.display_name	Tyler J. Nielsen
authorships[20].author_position	middle
authorships[20].raw_author_name	Tyler J. Nielsen
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5070615133
authorships[21].author.orcid	https://orcid.org/0000-0001-9635-1339
authorships[21].author.display_name	Jérôme Galon
authorships[21].author_position	middle
authorships[21].raw_author_name	Jerome Galon
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5085745169
authorships[22].author.orcid	https://orcid.org/0000-0002-2075-3224
authorships[22].author.display_name	Matthew G. Varga
authorships[22].author_position	middle
authorships[22].raw_author_name	Matthew Gordon. Varga
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5010230522
authorships[23].author.orcid	https://orcid.org/0000-0003-0178-5594
authorships[23].author.display_name	Brock L. Schweitzer
authorships[23].author_position	middle
authorships[23].raw_author_name	Brock L. Schweitzer
authorships[23].is_corresponding	False
authorships[24].author.id	https://openalex.org/A5081985776
authorships[24].author.orcid	https://orcid.org/0000-0002-0520-4841
authorships[24].author.display_name	Chiara Cremolini
authorships[24].author_position	last
authorships[24].raw_author_name	Chiara Cremolini
authorships[24].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	http://doi.org/10.1158/1078-0432.27030781.v1
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11067
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.996399998664856
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	Colorectal Cancer Treatments and Studies
related_works	https://openalex.org/W4248636606, https://openalex.org/W3024972238, https://openalex.org/W4401573389, https://openalex.org/W4388045576, https://openalex.org/W2186633408, https://openalex.org/W2788599721, https://openalex.org/W2706973099, https://openalex.org/W2955392295, https://openalex.org/W4393216394, https://openalex.org/W4252058598
cited_by_count	0
locations_count	2
best_oa_location.id	doi:10.1158/1078-0432.27030781.v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	http://doi.org/10.1158/1078-0432.27030781.v1
primary_location.id	doi:10.1158/1078-0432.27030781.v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	http://doi.org/10.1158/1078-0432.27030781.v1
publication_date	2024-09-16
publication_year	2024
referenced_works_count	0
abstract_inverted_index.IO	14, 20
abstract_inverted_index.in	6
abstract_inverted_index.of	3
abstract_inverted_index.to	13, 18
abstract_inverted_index.(a)	16
abstract_inverted_index.HR:	27
abstract_inverted_index.NR:	30
abstract_inverted_index.and	17, 22, 45
abstract_inverted_index.arm	24, 34, 40
abstract_inverted_index.not	31
abstract_inverted_index.the	7
abstract_inverted_index.(b).	25
abstract_inverted_index.both	19
abstract_inverted_index.plus	37, 43
abstract_inverted_index.Atezo	39
abstract_inverted_index.Meier	1
abstract_inverted_index.hazard	28
abstract_inverted_index.ratio,	29
abstract_inverted_index.status	15, 21
abstract_inverted_index.Control	33
abstract_inverted_index.Legend:	26
abstract_inverted_index.overall	8
abstract_inverted_index.reached.	32
abstract_inverted_index.survival	5
abstract_inverted_index.FOLFOXIRI	36, 42
abstract_inverted_index.according	12
abstract_inverted_index.estimates	2
abstract_inverted_index.indicates	35, 41
abstract_inverted_index.treatment	23
abstract_inverted_index.(optimized	10
abstract_inverted_index.population	9
abstract_inverted_index.bevacizumab	44
abstract_inverted_index.cut-point),	11
abstract_inverted_index.bevacizumab.	38
abstract_inverted_index.<p>Kaplan	0
abstract_inverted_index.progression-free	4
abstract_inverted_index.atezolizumab.</p>	46
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	25
citation_normalized_percentile.value	0.32382051
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False